
Opinion|Videos|August 1, 2024
ctDNA to Inform Adjuvant Therapy and the CIRCULATE Trial
Medical professionals explore methods for integrating circulating tumor DNA results with radiographic and pathologic findings to optimize patient care.
Advertisement
Episodes in this series

- How do you factor ctDNA into treatment selection and management?
- How do you integrate ctDNA with radiographic or pathologic correlates?
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer
2
Lung Cancer Survival Rate Climbs to 31%, Although Screening Gaps Persist
3
Galinpepimut-S Improves Overall Survival in Phase 3 AML Maintenance Trial
4
FDA Grants Final Approval to Generic Binimetinib in BRAF-Mutant Melanoma, NSCLC
5

